Vardis Proud To Support IMV Technologies and Montagu Private Equity in Appointing Joachim Hasenmaier as Chairman
Joachim Hasenmaier joins IMV Technologies as Chairman
Dr. Hasenmaier was most recently a member of the board of managing directors of Boehringer Ingelheim, a world-leading, research-driven pharmaceutical company, where he oversaw the animal health and consumer health care businesses. Previously, as head of animal health of Boehringer Ingelheim, he led the rapid growth and expansion of the business, including the acquisition of a significant part of the Fort Dodge Animal Health product portfolio as well as the successful acquisition and integration of the Sanofi/Merial animal health units. Dr. Hasenmaier received his doctor of veterinary medicine (Dr.med.vet.) degree from the University of Munich and his MBA from the Kellogg School of Management at Northwestern University.
IMV Technologies, a Montagu Business, is the world leader in animal artificial insemination, embryo transfer and veterinary imaging. Founded in 1963, IMV Technologies, a French company, has subsidiaries and/or manufacturing facilities in Brazil, China, France, India, Italy, the Netherlands, Russia, Scotland, South Africa, and the United States. IMV Technologies operates leading brands in the areas of semen analysis, assisted reproduction, artificial insemination, and veterinary imaging. IMV Technologies’ Life Sciences division, CryoBio System, manufactures and distributes equipment and supplies for human assisted reproduction and biobanking.